Lv7
4965 积分 2021-06-10 加入
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma
13天前
已完结
Arlocabtagene autoleucel-a GPRC5D-targeted CAR T-cell therapy in heavily pretreated relapsed/refractory multiple myeloma
13天前
已完结
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
1个月前
已完结
Antibody–Drug Conjugates in SCLC: DLL3, B7-H3, TROP2, and Beyond
1个月前
已完结
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
1个月前
已完结
Assessment of delta-like ligand 3 (DLL3) immunostaining in neuroendocrine tumors of the gynecological tract and comparing expression with other high-grade gynecological malignancies
1个月前
已完结
Truncated N-terminal mutants of SV40 large T antigen as minimal immortalizing agents for CNS cells
2个月前
已完结
T-ICAHT: Grading and Prognostic Impact of Thrombocytopenia After CAR T-cell Therapy
3个月前
已完结
In Vivo CAR-t generation using an engineered lentiviral vector platform targeting BCMA, CD19 and CD20
3个月前
已完结
Bridging radiotherapy before CAR-T therapy in CNS lymphoma
3个月前
已完结
皖公网安备34019202002308
